• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Genentech

Genentech

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Mallinckrodt Announces Key Leadership Appointments Following Completion of Questcor Acquisition

    Mallinckrodt Announces Key Leadership Appointments Following Completion of Questcor Acquisition

  2. Genentech Submits Supplemental Biologics License Application to FDA for Lucentis Indication in Diabetic Retinopathy

    Genentech Submits Supplemental Biologics License Application to FDA for Lucentis Indication in Diabetic Retinopathy

  3. Research and Markets: Growth Factors (Blood and Tissue) Market 2014 - Global Strategic Business Report

    Research and Markets: Growth Factors (Blood and Tissue) Market 2014 - Global Strategic Business Report

  4. ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2014 Financial Results

    ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2014 Financial Results

  5. Drug Companies Oppose Moves to Reimburse Off-Label Medicine

    Drug Companies Oppose Moves to Reimburse Off-Label Medicine

  6. Social Security Tips For Couples

    Genentech DNA reported strong first-quarter revenue and earnings growth compared with the year-ago period, and we are sticking with our fair value estimate. As the company warned at its investor meeting in March, quarter-over-quarter product sales growth was stagnant, while total revenue growth ...

  7. Tuttle Tactical Management Weekly Market Commentary

    Genentech DNA continues to focus attention on its commercial lineup, making its slimmer early-stage pipeline not worrisome yet. The biotech firm has additional clinical trials and hopes to expand indications for each of its largest products, including Avastin, Herceptin, and Rituxan. According to ...

  8. Reinvent Your Practice: Alternatives to Traditional Succession Planning

    Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...

  9. Share Repurchase: Potential Signal of Undervaluation and Outperformance

    Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.